Tofacitinib citrate - TWi Biotechnology
Alternative Names: AC-1101; IMG 003Latest Information Update: 28 Nov 2023
At a glance
- Originator TWi Biotechnology
- Developer Inmagene; TWi Biotechnology
- Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Granuloma annulare
- Preclinical Atopic dermatitis
- No development reported Vitiligo
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Vitiligo(In volunteers) in Canada (Topical, Gel)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Vitiligo in Taiwan (Topical, Gel)
- 28 Sep 2022 Phase-I clinical trials in Granuloma annulare (In adults, In the elderly) in USA (Topical) (NCT05580042)